《贝特类药物在血脂治疗中的作用课件》由会员分享，可在线阅读，更多相关《贝特类药物在血脂治疗中的作用课件（18页珍藏版）》请在金锄头文库上搜索。
1、,C,O,O,C,CH3,COO,CH,CH3,CH3,Cl,CH3,O,C,CH3,COOC2H5,CH3,Cl,CH3,CH3,O,CH3,COOH,CH3,C,Fenofibrate,Clofibrate,Gemfibrozil,Effect of Drugs on LDL-C Levels,Effect of Drugs on Triglyceride and HDL-C Levels,Fibric Acid Derivatives,Goldberg AC, et al. Clin Ther. 1989;11:69-83.,*These are mean percentage chan
2、ges, not percentage changes in means. NS=Not statistically significant when compared to placebo (12% increase).,Fenofibrate for the Treatment of Type IV and V Hyperlipoproteinemias A Double-Blind, Placebo-Controlled Multicenter US Study,Fenofibrate for the Treatment of Type IV and V Hyperlipoprotein
3、emias A Double-Blind, Placebo-Controlled Multicenter US Study,Goldberg AC, et al. Clin Ther. 1989;11:69-83.,*These are mean percentage changes, not percentage changes in means.,Goldberg AC, et al. Clin Ther. 1989;11:69-83.,Fenofibrate for the Treatment of Type IV and V Hyperlipoproteinemias A Double
4、-Blind, Placebo-Controlled Multicenter US Study,Many patients with markedly elevated triglycerides have reduced LDL-C levels because of a derangement in the normal composition of LDL. This derangement produces a triglyceride-rich and cholesterol-depleted LDL. When triglycerides are reduced with ther
5、apy, the composition of LDL normalizes. This can elevate LDL-C levels.,Effects of Fenofibrate on Plasma Lipids Double-Blind, Multicenter Study in Patients with Type IIa or IIb Hyperlipidemia,Brown WV, et al. Arteriosclerosis. 1986; 6:670-678.,p0.10,(Randomized, Crossover Study),Farnier M, et al. Arc
6、h Int Med. 1994;154:441-449.,Fenofibrate 200 mg/day,Simvastatin 20 mg/day,Simvastatin 20 mg/day,Fenofibrate 200 mg/day,Type IIa, n=16 Type IIb, n=14,Type IIa, n=16 Type IIb, n=14,Group 1,Group 2,I I I I I I I 0 3 6,Months,Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in P
7、atients with Primary Type IIa or IIb Hyperlipidemia,Fenofibrate vs. Simvastatin Effect on Overall Lipid Profile,Farnier M, et al. Arch Int Med. 1994;154:441-449.,(Type IIa),% Change from Baseline,NC,NC=no change,NC,NC,Fenofibrate vs. Simvastatin Effect on Overall Lipid Profile,Farnier M, et al. Arch
8、 Int Med. 1994;154:441-449.,(Type IIb),% Change from Baseline,Angiographic Studies in LowHDL-C Subjects,Lipoprotein and Coronary Atherosclerosis Study (LCAS) Post Coronary Artery Bypass Graft Trial (Post-CABG) Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) Lopid Coronary Angiography Trial (LOCAT),VA-HIT: Design,Hypothesis: Gemfibrozil treatment of “isolated” low HDL-C will 2 CHD events. Subjects: 2531 male veterans 2.0) - Concomitant medications: Itraconazole, Ketoconazole Cyclosporin A Erythromycin- Age 70 years,
